Lv3
228 积分 2023-11-07 加入
Practical Management of Bispecific Antibodies in Multiple Myeloma
14天前
已完结
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML
28天前
已完结
The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
1个月前
已完结
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy
1个月前
已完结
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies
1个月前
已完结
Cardiovascular Safety Across Leading BTK Inhibitors in Relapsed/Refractory CLL: Results of a Network Meta‐Analysis
1个月前
已完结
Efficacy and Safety of Autologous Stem Cell Transplantation in First-Line Treatment and at Relapse in Elderly Patients with Multiple Myeloma
3个月前
已完结
SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM
3个月前
已完结
Classic Hodgkin Lymphoma in the Older Adult
3个月前
已关闭
Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study
3个月前
已完结
皖公网安备34019202002308
